Free Trial
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

ANI Pharmaceuticals logo
$66.10 +0.79 (+1.21%)
Closing price 04:00 PM Eastern
Extended Trading
$66.08 -0.02 (-0.02%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

Key Stats

Today's Range
$64.86
$66.58
50-Day Range
$57.27
$72.95
52-Week Range
$52.50
$77.00
Volume
397,542 shs
Average Volume
314,923 shs
Market Capitalization
$1.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.88
Consensus Rating
Buy

Company Overview

ANI Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

ANIP MarketRank™: 

ANI Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 306th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    ANI Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about ANI Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for ANI Pharmaceuticals are expected to grow by 9.07% in the coming year, from $3.86 to $4.21 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ANI Pharmaceuticals is -52.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ANI Pharmaceuticals is -52.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ANI Pharmaceuticals has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ANI Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.44% of the float of ANI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ANI Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in ANI Pharmaceuticals has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ANI Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    ANI Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.44% of the float of ANI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ANI Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in ANI Pharmaceuticals has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    6 people have searched for ANIP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $346,854.00 in company stock.

  • Percentage Held by Insiders

    11.10% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ANI Pharmaceuticals' insider trading history.
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Stock News Headlines

Why Volatility Keeps Coming Back — And How I Trade It
Volatility isn’t the enemy — it’s the opportunity. While most traders panic during market swings, Jeff Clark uses a three-step method to target quick wins from VIX spikes and sudden price moves. It works in any market direction… and he’s showing how it works in a free video, available now.
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead
See More Headlines

ANIP Stock Analysis - Frequently Asked Questions

ANI Pharmaceuticals' stock was trading at $55.28 at the beginning of 2025. Since then, ANIP shares have increased by 19.6% and is now trading at $66.11.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its earnings results on Friday, May, 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The firm's revenue was up 43.4% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of ANI Pharmaceuticals include Kings Path Partners LLC (0.05%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Chad Gassert, Stephen P Carey, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Krista Davis, Antonio R Pera and Renee P Tannenbaum.
View institutional ownership trends
.

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/09/2025
Today
7/10/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
CIK
1023024
Employees
600
Year Founded
N/A

Price Target and Rating

High Price Target
$94.00
Low Price Target
$65.00
Potential Upside/Downside
+22.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
16.92
P/E Growth
N/A
Net Income
-$18.52 million
Pretax Margin
-4.09%

Debt

Sales & Book Value

Annual Sales
$614.38 million
Cash Flow
$7.63 per share
Price / Cash Flow
8.56
Book Value
$19.11 per share
Price / Book
3.42

Miscellaneous

Free Float
19,258,000
Market Cap
$1.41 billion
Optionable
Optionable
Beta
0.57

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ANIP) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners